INVESTOR RELATIONS
We believe our technology is a profound scientific breakthrough that could lead to a new paradigm for the identification, characterization and treatment of the multifactorial upstream etiology of CVD and other vascular pathophysiologies leading to predictive, curative and ultimately preventive outcomes.
Embotricin to 1st Exit Timeline
Scientific Breakthrough?
Historical development of antibiotic targeting microorganisms leading to cure of infectious disease. An equivalent approach is to target endothelial glycocalyx to cure CVD by an antiembolic™ mechanism.
